Lasa Supergenerics Ltd
NSE: LASA BSE: 540702
Incorporated in 2016, Lasa Supergenerics Ltd is in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc.[1]
₹7.8
52W: ₹5.65 — ₹19
PE 145 · Book ₹11.2 · -30% vs bookMarket Cap₹39.1 Cr
Stock P/E145Price to Earnings
ROCE1%Return on Capital
ROE1.01%Return on Equity
Div. Yield0%Face Value ₹10
Strengths
- +Company has reduced debt.
- +Stock is trading at 0.67 times its book value
Weaknesses
- −Company has low interest coverage ratio.
- −The company has delivered a poor sales growth of -3.16% over past five years.
- −Company has a low return on equity of -9.72% over last 3 years.
- −Company's cost of borrowing seems high
Shareholding Pattern
Promoters53.65%
FIIs0%
DIIs0%
Public46.35%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% |
| FIIs | 0% | 0.01%▲0.0 | 0%▼0.0 | 0% | 0.47%▲0.5 | 0%▼0.5 | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 46.34% | 46.32%▼0.0 | 46.35%▲0.0 | 46.35% | 45.88%▼0.5 | 46.35%▲0.5 | 46.34%▼0.0 | 46.35%▲0.0 |
Financial Statements
| Metric | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24.3 | 26.66 | 22.82 | 30.84 | 39.39 | 33.08 | 39.14 | 20.01 | 3.06 | 2.2 |
| Expenses | 23.25 | 25.6 | 26.81 | 29.04 | 38.6 | 32.81 | 35.73 | 20.51 | 7.06 | 2.95 |
| Operating Profit | 1.05 | 1.06 | -3.99 | 1.8 | 0.79 | 0.27 | 3.41 | -0.5 | -4 | -0.75 |
| OPM % | 4.32% | 3.98% | -17.48% | 5.84% | 2.01% | 0.82% | 8.71% | -2.5% | -130.72% | -34.09% |
| Net Profit | -0.02 | -1.46 | -15.3 | -2.73 | -3.23 | 5.49 | -14.29 | -21.12 | -6.25 | -2.55 |
| EPS ₹ | 0 | -0.29 | -3.05 | -0.54 | -0.64 | 1.1 | -2.85 | -4.22 | -1.25 | -0.51 |
AI Insights
Revenue Trend
TTM revenue at ₹64Cr, down 54.9% YoY. OPM at -3%.
Debt Position
Borrowings at ₹7Cr. Debt-to-equity ratio: 1.17x. High leverage — monitor closely.
Institutional Flow
DIIs: 0% (+0.00pp change). FIIs: 0% (+0.00pp change). Promoters hold 53.65%.
Margin & Efficiency
ROCE declining from 0% (Mar 2016) to -1% (Mar 2025). Working capital days: 37.
Valuation
PE 145x with 1% ROCE. Price is -30% above book value of ₹11.2. Dividend yield: 0%.
Recent Announcements
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12 May - Submitted Regulation 74(5) certificate for quarter and year ended March 31, 2026.
- Declaration With Respect To Non -Applicability Of Large Entities 16 Apr - Company declares it is not a Large Corporate under SEBI debt-fundraising framework.
- Closure of Trading Window 30 Mar - Trading window closed Apr 1, 2026 until 48 hours after audited results for quarter/year ended Mar 31, 2026.
- Integrated Filing For Quarter Ended December 31, 2025 13 Feb - May 18, 2025 fire: uninsured losses Rs 2,057.47 lakhs; operations halted; Q3 results approved.
- Results For Quarter Ended 31St December 2025 13 Feb
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse